- Report
- March 2019
- 17 Pages
Global
€8886EUR$10,000USD£7,659GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$4,220USD£3,122GBP
- Report
- February 2024
- 89 Pages
Global
From €3500EUR$4,220USD£3,122GBP
- Report
- March 2025
- 211 Pages
China
From €3554EUR$4,000USD£3,063GBP
The Major Depressive Disorder Drug market is a subset of the Mental Disorders Drugs market. It is composed of pharmaceuticals used to treat major depressive disorder, a mental health disorder characterized by persistent feelings of sadness, loss of interest, and fatigue. These drugs are typically prescribed by psychiatrists and other mental health professionals. Commonly prescribed drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs).
The Major Depressive Disorder Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and Novartis. Show Less Read more